Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 QIAGEN Expands NGS Assay Portfolio | Contract Pharma

What are you searching for?

Sign in
Breaking News

QIAGEN Expands NGS Assay Portfolio

To add nine GeneRead DNAseq panels

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

QIAGEN N.V. plans to expand its portfolio of molecular assays used in next-generation sequencing (NGS) for use in clinical research and diagnostics. The current portfolio of nine GeneRead DNAseq panels is being expanded to approximately 20 during the course of 2013.
 
QIAGEN is creating these new gene panels for targeted NGS analysis based on the GeneGlobe portfolio of more than 60,000 annotated molecular assays. These products are designed to be used on any NGS platform, and according to the company, integrate seamlessly into the sample-to-result NGS workflow that includes the QIAGEN GeneReader platform.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics